top of page
Browse by category
Search
Napo Pharmaceuticals files patent application for crofelemer to mitigate GLP-1 side-effects
Napo Pharmaceuticals has filed a broad defining provisional patent application with the US Patent and Trademark Office (USPTO) for...
RYGB and SG lower health care costs for T2DM patients
In patients with type 2 diabetes, Roux-en-Y gastric bypass and sleeve gastrectomy for weight loss may be effective for reducing long-term...
FDA approves semaglutide to reduce the risk of worsening kidney disease and cardiovascular death
The FDA has approved Ozempic to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease) and death due to...
Journal Watch 29/1/2025
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
SPECCIAL study: BMS significantly lowers future progression of cirrhosis
Patients with obesity and fatty liver-related cirrhosis who had bariatric surgery significantly lowered their future risk of developing...
CMS approves new quality measure tied to GLP-1 use and pulmonary aspiration
The Centers for Medicare & Medicaid Services (CMS) formally approved a new quality measure developed by the Quality Team at North...
Browse by tag
bottom of page